TICKERNERD
Menu
DYNDYNHealthcare · Biotechnology

DYN Stock Forecast: Dyne Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$25
+0.24% on the day

The 17 Wall Street analysts covering Dyne Therapeutics, Inc. hold a median 12-month price target of $40 — +58.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.7B
Ticker Nerd rank
27 / 100
Median analyst target
$40
Analysts covering
17
Total return, dividends reinvested
1W
−1.5%
1M
+9.4%
YTD
+29.0%
1Y
+151.1%
From 52W high
−2.5%
From 52W low
+146.2%
$10
$26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DYN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dyne Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Value
58
Growth
52
Quality
50
Volatility
34
Accruals
34
Revisions
26
Size
25
Issuance
8

Momentum (94): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Dyne Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

DYN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DYN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26DYNHigh $50Median $40Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $17Median $40High $50

The green dot is the last close — the median target sits +58.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 July 2026Morgan StanleyMaintainsOverweight$47 → $45
30 July 2026RBC CapitalMaintainsOutperform$30 → $35
23 July 2026Cantor FitzgeraldInitiatesOverweight—
23 July 2026Cantor FitzgeraldInitiatesOverweight—
26 June 2026TD CowenInitiatesBuy—
26 June 2026TD CowenInitiatesBuy—
15 May 2026Evercore ISI GroupMaintainsOutperform—
13 May 2026BernsteinMaintainsMarket Perform—
9 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Mar 2026Morgan StanleyMaintainsOverweight—
20 Jan 2026JP MorganMaintainsNeutral—
15 Dec 2025Evercore ISI GroupMaintainsOutperform—
11 Dec 2025StifelMaintainsBuy—
10 Dec 2025OppenheimerUpgradeOutperform—
9 Dec 2025Chardan CapitalMaintainsBuy—
9 Dec 2025Morgan StanleyMaintainsOverweight—
8 Dec 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025JP MorganMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

DYN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
6
Fundamentals

Dyne Therapeutics, Inc. (DYN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.2×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
5.9×

Cheaper than 18% of US stocks

EV / EBITDA
−7.5×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.6%

Higher than 15% of US stocks

Return on assets
−39.0%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DYN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DYNDyne Therapeutics, Inc.$4.7B
27
CRSPCRISPR Therapeutics AG$4.6B
19
CAICaris Life Sciences, Inc.$4.4B
30
TNGXTango Therapeutics, Inc.$4.4B
57
ACADACADIA Pharmaceuticals, Inc.$4.4B
65
MANEVeradermics, Inc.$4.3B
1
TVTXTravere Therapeutics, Inc.$5.0B
94
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DYN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest DYN news & analysis

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 29 July 2026positive

Dyne Therapeutics reported its second quarter 2026 financial results and highlighted that the FDA accepted its Biologics License Application for z-rostudirsen in exon 51 Duchenne muscular dystrophy, granting Priority Review with a PDUFA target action date of January 21, 2027.

Why it matters — The FDA acceptance and Priority Review of the BLA bring z-rostudirsen, Dyne's key therapeutic candidate, one step closer to potential approval, a major regulatory milestone for the company.

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

GlobeNewsWire · 28 July 2026positive

The U.S. FDA has cleared Dyne Therapeutics' Investigational New Drug (IND) application for DYNE-302, a treatment for Facioscapulohumeral Muscular Dystrophy (FSHD), marking the company's third program to enter clinical development using its FORCE platform.

Why it matters — This clearance expands Dyne's clinical pipeline to a third program, demonstrating continued advancement of its FORCE platform in rare neuromuscular diseases.

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 24 July 2026neutral

Dyne Therapeutics announced it has granted inducement equity awards to 12 newly hired employees as a material inducement for them to accept employment with the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — DYN watchers may note the hiring of 12 new employees signals continued investment in the company's workforce as it advances its clinical-stage programs for neuromuscular diseases.

FAQ

Frequently asked questions about DYN stock

What is the DYN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Dyne Therapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $17 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DYN stock a buy right now?

Of the 17 analysts covering Dyne Therapeutics, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dyne Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DYN?

As at 1 Aug 2026, Dyne Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will DYN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +58.5% from the last close, and Ticker Nerd's factor model ranks Dyne Therapeutics, Inc. 27 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DYN stock forecast for 2030?

No analyst covering Dyne Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DYN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $50 over the next 12 months.

How has DYN stock performed over the past year?

Dyne Therapeutics, Inc. returned +151.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dyne Therapeutics, Inc. do?

Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted RNA therapies designed to overcome delivery limitations to muscle tissue and the central nervous system.

What is the latest news on DYN?

The most recent item we track (GlobeNewsWire, 29 July 2026): "Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights". Dyne Therapeutics reported its second quarter 2026 financial results and highlighted that the FDA accepted its Biologics License Application for z-rostudirsen in exon 51 Duchenne muscular dystrophy, granting Priority Review with a PDUFA target action date of January 21, 2027.

Company

About Dyne Therapeutics, Inc.

Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted RNA therapies designed to overcome delivery limitations to muscle tissue and the central nervous system. Dyne's lead programs address significant unmet medical needs in conditions including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company is advancing multiple candidates through clinical development, with key programs progressing toward regulatory milestones and potential commercialization. Dyne operates in the rare disease biotechnology space, serving patients with limited treatment options and positioning itself for potential market entry as its pipeline candidates mature toward approval and launch.

CEO Mr. John G. Cox M.B.A. · 289 employees · United States · https://www.dyne-tx.com